Becton, Dickinson and Company and Pfizer Inc. are Dominating the Market for Global Injectable Drug Delivery Market in 2017

Global Injectable Drug Delivery Market is expected to reach USD 1,104,096.5 million by 2025 from USD 378,998.2 million in 2017, at a CAGR of 12.4% in the forecast period 2018 to 2025. The new market report contains data for historic years 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

Global Injectable Drug Delivery Market Get Free Report Sample: http://databridgemarketresearch.com/reports/global-injectable-drug-delivery-market/

The global injectable drug delivery market is highly concentrated to a few big players and rest to local players who cater to domestic markets only. Baxter International, Inc., Becton Dickinson and Company, Gerresheimer AG, Pfizer, Inc., Schott AG, Alkermes Plc., Eli Lilly and Company, Sandoz, Terumo Corporation, Teva Pharmaceuticals Industries Ltd., Ypsomed, and Bespak, among other players

BECTON, DICKINSON AND COMPANY

Founded in 1897 as Becton, Dickinson and Company and head quartered in New Jersey, U.S. is focused on developing, manufacturing and sales of medical supplies, devices, laboratory equipment and diagnostic products. The company operates through two business segments: BD Medical and BD Life Sciences. Its medical segment business unit includes Diabetes Care, Medication and Procedural Solutions, Medication Management Solutions, and Pharmaceutical Systems. These business units’ segmentsincludeneedles and syringes, intravenous catheters, self-injection system, insulin syringes and pen needles, prefilled IV flush syringes products.

The company's operations span across North & South America, Europe, Australia, China, India, Japan, Korea, Taiwan and South East Asia. Some of its subsidiaries include Accuri Cytometers, Inc. (Delaware), BD Holding S. de R.L. de C.V. (Mexico), Becton Dickinson AcuteCare Holdings, Inc. (Delaware), Becton Dickinson Asia Limited (Hong Kong), Becton Dickinson Austria GmbH (Austria), CareFusion Corporation (Delaware, and U.K. Medical, Ltd. (U.K.) among others

PFIZER:

Incorporated in June 1942 and headquartered in New York, U.S. Pfizer Inc., is engaged in discovering, developing and, manufacturing of healthcare products. Pfizer Inc., operates through two segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The Company's IH segment concentrates on creating and commercializing immunizations and prescriptions that enhance patients' lives, and in addition products for the end user health care. Its therapeutic regions incorporate oncology, antibodies, cardiovascular, metabolic, irritation, immunology, neuroscience, torment, uncommon illnesses and purchaser human services. The Company's EH portion incorporates legacy brands that have lost or will soon lose market superiority in both rising and developed markets, biosimilars marked generics, generic sterile injectable products and mixture frameworks. EH segment additionally incorporates another EH innovative work association, and additionally contract manufacturing business.

The company has a strong geographic presence in more than 40 countries across North America, Latin America, Europe, Eastern Europe, the Middle East, Africa, and Asia-Pacific, with manufacturing units in Europe, the Middle East and Africa, Asia-Pacific, Japan, Latin America, and the U.S. The subsidiaries of the company include Agouron Pharmaceuticals (U.S.), G.D. Searle & Company (U.S.), Innopharma (U.S.), Greenstone (U.S.), Parke-Davis (U.S.), and Pfizer (U.K.)

BAXTER INTERNATIONAL:

Founded in 1931 and headquartered in Illinois, U.S., Baxter International, Inc. manufactures medical devices, pharmaceuticals, and biotechnology products. The company operates through two business segments, namely, BioScience and Medical Products. The company provides a wide range of products for the treatment of hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. Through the Medical Products segment, the company offers intravenous solutions, administration and nutrition sets, drug reconstitution systems, prefilled syringes (with and without needles) and vials, and infusion pumps and inhalation anesthetics. On the other hand, the BioScience business segment focuses on the treatment of hemophilia and other bleeding disorders by processing recombinant and plasma-based proteins.

The company has a strong geographic presence across the globe, spanning North America, Europe, the Middle East, Africa, Latin America, and Asia-Pacific. The company has three subsidiaries, namely, Gambro (U.S.), Baxter Healthcare Corporation (U.S.), and Baxter World Trade Corporation (U.S.).